Thymoma recurrence presents a distinct clinical challenge requiring a structured, evidence-informed approach. The options available differ meaningfully from initial management and are guided by the extent and operability of recurrent disease.
This protocol addresses patients with recurrent thymoma — disease that has returned following prior treatment. Management is shaped by the pattern of recurrence and whether the disease remains surgically accessible.
Systemic therapy is the primary modality for inoperable recurrence, with single-agent therapy generally preferred in that setting. Multiple classes of treatment may be considered depending on individual patient factors, including chemotherapy agents and targeted biological therapies. In carefully selected cases, surgery or radiation may also play a role.
Full regimen details, sequencing, and eligibility criteria are in the complete protocol.